{"classes":[{"categories":[{"measurements":[{"comment":"Not Reached","groupId":"OG000","lowerLimit":"23.3","upperLimit":"NA","value":"NA"},{"comment":"Not Reached","groupId":"OG001","lowerLimit":"16","upperLimit":"NA","value":"71.7"},{"comment":"Not Reached","groupId":"OG002","lowerLimit":"19","upperLimit":"NA","value":"67.8"},{"comment":"Not Reached","groupId":"OG003","lowerLimit":"16","upperLimit":"NA","value":"69"},{"groupId":"OG004","lowerLimit":"16.6","upperLimit":"51.3","value":"28.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"29"}],"units":"Participants"}],"description":"The distribution will be estimated by the methods of Kaplan and Meier. The estimates of survival at specific time points will be calculated (eg, median, 6 month survival).","dispersionType":"95% Confidence Interval","groups":[{"description":"Liposarcoma patients receive alisertib PO BID on days 1-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Cohort 1"},{"description":"Leiomyosarcoma patients receive alisertib PO BID on days 1-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"Cohort 2"},{"description":"Undifferentiated Sarcoma patients receive alisertib PO BID on days 1-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.","id":"OG002","title":"Cohort 3"},{"description":"Malignant Peripheral Nerve Sheath Tumor patients receive alisertib PO BID on days 1-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.","id":"OG003","title":"Cohort 4"},{"description":"Other Sarcoma patients receive alisertib PO BID on days 1-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.","id":"OG004","title":"Cohort 5"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"The time between registration and death, assessed up to 18 months","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Weeks"}